Phase 1 Motor Neurone Disease Trial, Recruiting (NCT07571200)

Phase 1 Motor Neurone Disease Trial, Recruiting NCT07571200 Sponsor: Eli Lilly and Company Condition: Motor Neurone Disease

Printed from Voxsanity (voxsanity.com.au) — NCT07571200 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Motor Neurone Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must have fully completed a related ("parent") study that was testing a treatment for ALS, including both the treatment period and any follow-up period after treatment ended (note: missing individual visits during that study does not disqualify you)

Who may not be able to join:

You had to permanently or temporarily stop taking the study medication during the parent study, and restarting it would be considered too risky for your safety by the study doctor
Your ALS progressed very severely during the parent study — for example, you needed to be placed on a permanent breathing machine — and the study doctor believes continued participation would be too risky
You experienced a serious, unresolved side effect or developed a new health condition (unrelated to ALS) during the parent study that the study doctor believes makes it unsafe for you to take the study medication or take part in study procedures

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Phone: 1-317-615-4559

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07571200

Sponsor: Eli Lilly and Company

Phase: Phase 1

Status: Recruiting

Condition: Motor Neurone Disease

Trial contact: 1-317-615-4559

More information: https://clinicaltrials.gov/study/NCT07571200

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must have fully completed a related ("parent") study that was testing a treatment for ALS, including both the treatment period and any follow-up period after treatment ended (note: missing individual visits during that study does not disqualify you)

Who may not be able to join:

You had to permanently or temporarily stop taking the study medication during the parent study, and restarting it would be considered too risky for your safety by the study doctor
Your ALS progressed very severely during the parent study — for example, you needed to be placed on a permanent breathing machine — and the study doctor believes continued participation would be too risky
You experienced a serious, unresolved side effect or developed a new health condition (unrelated to ALS) during the parent study that the study doctor believes makes it unsafe for you to take the study medication or take part in study procedures

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

Eli Lilly and Company

Registry

ClinicalTrials.gov

Start date

14 May 2026

Est. completion

1 June 2029

Where this trial is recruiting

🇧🇪 Belgium 🇨🇦 Canada 🇩🇪 Germany 🇳🇱 Netherlands 🇪🇸 Spain

Primary endpoints

Number of Participants Allocated to Each of the Intervention-Specific Appendices (ISA)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov